TC-99M SESTAMIBI AND OTHER AGENTS IN THE DETECTION OF METASTATIC MEDULLARY CARCINOMA OF THE THYROID

被引：30

作者：

LEBOUTHILLIER, G

MORAIS, J

PICARD, M

PICARD, D

CHARTRAND, R

DAMOUR, P

机构：

[1] UNIV MONTREAL,HOP ST LUC,DEPT NUCL MED,1058 ST DENIS ST,MONTREAL H2X 3J4,PQ,CANADA

[2] UNIV MONTREAL,HOP ST LUC,DEPT ENDOCRINOL,MONTREAL H3C 3J7,QUEBEC,CANADA

来源：

CLINICAL NUCLEAR MEDICINE | 1993年 / 18卷 / 08期

关键词：

D O I：

10.1097/00003072-199308000-00005

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

The 10-year survival rate for medullary carcinoma of the thyroid (MCT) is 50%; thus, good tumor-seeking radiopharmaceuticals are needed to localize foci of recurrence and metastasis during follow-up. Two patients with metastatic MCT were studied with Tl-201, I-131 MIBG, Tc-99m (V)-DMSA, and Tc-99m MIBI. A SPECT study with the latter agent allowed the visualization and precise localization of a metastatic mediastinal lymph node. More studies need to be done to evaluate the role of Tc-99m MIBI in the detection of recurrence and metastases of MCT.

引用

页码：657 / 661

页数：5

共 11 条

[1]

BRAVERMAN LE, 1986, WERNERS THYROID, P1349

[2]

Cabezas R C, 1989, Henry Ford Hosp Med J, V37, P169

[3]

DEGROOT LJ, 1989, ENDOCRINOLOGY, V2, P1132

[4]

GUERRA U, 1988, J NUCL MED ALLIED S, V32, P242

[5] NEW TRACERS FOR THE IMAGING OF THE MEDULLARY-THYROID CARCINOMA [J].

GUERRA, UP ;

PIZZOCARO, C ;

TERZI, A ;

GIUBBINI, R ;

MAIRA, G ;

PAGLIAINI, R ;

BESTAGNO, M .

NUCLEAR MEDICINE COMMUNICATIONS, 1989, 10 (04) :285-295

[6] MEDULLARY-THYROID CARCINOMA - LOCALIZATION OF A MEDIASTINAL METASTASIS WITH I-131 MIBG [J].

LAFLAMME, L ;

TAILLEFER, R ;

DURANCEAU, A ;

VERDY, M ;

SCHURCH, W .

CLINICAL NUCLEAR MEDICINE, 1988, 13 (08) :577-579

[7]

REINERS C, 1986, NUKLEARMED-NUCL MED, V25, P22

[8]

Sandrock D, 1989, Henry Ford Hosp Med J, V37, P173

[9]

SIMPSON WJ, 1990, OTOLARYNG CLIN N AM, V23, P509

[10]

SONE T, 1985, J NUCL MED, V26, P604

← 1 2 →